ABSTRACT

Bedaquiline has been recently approved drug moiety for the treatment of pneumonic multidrug-safe tuberculosis (TB) as a component of mixed treatment in adults. Existing medicines for multi-drug safe tuberculosis (MDR-TB) have significant limitations, to the extent of their feasibility, result profile, and unconventionality of association. Bedaquiline is a novel diarylquinoline against microbial that has starting late been investigated as an assistant to existing medicines for MDR-TB. In this review, the overall properties of bedaquiline were consolidated like physicochemical properties, dose administration, mechanism of action, pharmacokinetics, pharmacodynamics,drug interactions, and side effects for better understanding. Keywords: bedaquiline, diarylquinoline, multidrug resistance, Mycobacterium tuberculosis, tuberculosis
Publication date: 01/10/2021

https://ijbpas.com/pdf/2021/October/MS_IJBPAS_2021_5662.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2021/10.10.5662